We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Oral CHOP‐like chemotherapy in 60–80 years‐old patients with diffuse large B‐cell lymphoma.
- Authors
Guidez, Stephanie; Lacotte‐Thierry, Laurence; Tomowiak, Cecile; Princet, Isabelle; Dreyfus, Brigitte; Olivier, Gaelle; Fleck, Emmanuel; Corby, Anne; Motard, Carine; Barrier, Jocelyn; Machet, Antoine; Le Dû, Katell; Debiais‐Delpech, Celine; Chabin, Michele; Leleu, Xavier; Guilhot, Joëlle; Delwail, Vincent
- Abstract
In this context, we developed a R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone)-like regimen: R-oroCIEP, an all-oral chemotherapy, for patients with diffuse large B-cell lymphoma (DLBCL). Second primary malignancies were reported in three patients: a fatal breast carcinoma observed 9 years post-treatment, a surgically cured lung cancer observed 2 years post-treatment and two skin cancers for the same patient: I in situ i melanoma and epidermal carcinoma, both surgically cured. However, our phase 1/2 study suggests that R-OroCIEP was safe and seemed to be as active as standard R-CHOP in first-line treatment for fit DLBCL patients aged 60-80 years. (2014) Significant dose escalation of idarubicin in the treatment of aggressive non-Hodgkin lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP- 14: 9-year follow up results of the CIVEP trial of the DSHNHL.
- Subjects
DIFFUSE large B-cell lymphomas; CANCER chemotherapy; HUMAN cell culture
- Publication
British Journal of Haematology, 2019, Vol 186, Issue 6, pe175
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.16056